$Sangamo Therapeutics(SGMO.US)$Sangamo Therapeutics To Present Neurology-Focused Pre-Clinical Data From Epigenetic Regulation, Capsid Delivery And Genome Engineering Platforms At 27th ASGCT Annual Meeting
The market anticipates continued poor revenue growth, potentially suppressing the P/S ratio. The company's forecast of declining revenue contributes to its low P/S. Without major changes, a drastic stock price increase seems unlikely.
$Sangamo Therapeutics(SGMO.US)$Sangamo Therapeutics Announces Data From STAC-BBB Demonstrating 'Robust Penetration of the Blood-brain Barrier (BBB) and Strong Transgene Expression Throughout the Central Nervous System (CNS) of NHPs'
Trytosaveabit楼主Benjamin’s:
It’s been on a pretty decent uptrend for 13 days now! In less than 30 days it’s gone from .39 to today high of 1.09! I’ve been in since just before Christmas! And I’m going to continue to ride for as long as I can! Hehehe. So I’m holding unless it drops below.73! GL
$Sangamo Therapeutics(SGMO.US)$Sangamo Therapeutics Announces FDA Alignment On Abbreviated Pathway To Potential Approval And EMA Prime Eligibility For ST-920 In Fabry Disease Benzinga· 2 mins ago - U.S. Food and Drug Administration (FDA) advises that a single study with up to 25 patients, in combination with confirmatory evidence, may be acceptable pathway to Biologics License Application (BLA) submission for isaralgagene civaparvovec, which would significantly reduce anticipated complexi...
Sangamo Therapeutics股票讨论区
Benzinga· 2 mins ago
- U.S. Food and Drug Administration (FDA) advises that a single study with up to 25 patients, in combination with confirmatory evidence, may be acceptable pathway to Biologics License Application (BLA) submission for isaralgagene civaparvovec, which would significantly reduce anticipated complexi...
暂无评论